Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.

CONCLUSIONS: Our study demonstrated that a shorter PSADT, a heavier volume of bone metastases, and a later treatment line before Ra-223 are poor prognostic factors for mCRPC patients. These newly discovered risk factors may help select patients who potentially have long-term OS after Ra-223 treatment.
PMID: 32875513 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - August 31, 2020 Category: Cancer & Oncology Authors: Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K Tags: Int J Clin Oncol Source Type: research